Promising CAR-T therapy for tough blood cancers hits snag – study withdrawn
NCT ID NCT05909527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new treatment called Anti-CD7 CAR-T for people with T-cell acute lymphoblastic leukemia or lymphoma that had come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei Yanda Hospital
Langfang, Hebei, 065000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.